Keeping Track: Aimmune’s Peanut Allergen Approved; Novartis’ Inclisiran, Pfizer/Lilly’s Tanezumab, Bayer’s Nifurtimox Submitted
Executive Summary
Highlights of the latest drug development news from our US FDA Performance Tracker.
You may also be interested in...
As US FDA Settles Into Teleworking, Will Application Reviews Be Affected?
Productivity may suffer under coronavirus-mandated telework despite workforce diligence, experts say.
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO On REMS Restrictions, Manufacturing
Aimmune CEO Jayson Dallas tells the Pink Sheet how physicians and patients are being certified to use Palforzia and how the product's food-based manufacturing process is actually an advantage.
Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions
The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.